News
Hosted on MSN3mon
New malaria vaccine shows high protection in clinical trial - MSNBoth GA2 and GA1 induced similar antibody titers against the P. falciparum circumsporozoite protein, suggesting enhanced protection with GA2 is associated with cellular immune responses rather ...
On April 12, 2023, participants were exposed to 50 (±5) GA2-infected or uninfected Anopheles stephensi mosquitoes. Six weeks later, all participants underwent a CHMI via bites from five wild-type ...
With the GA2 vaccine, the parasite reproduced over a longer period of time – up to a week – which allowed the immune system more time to recognise and begin fighting it.
Adverse events were similar across the trial groups. Protective efficacy against subsequent controlled human malaria infection was observed in 8 of 9 participants (89%) in the GA2 group, in 1 of 8 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results